| Description: |
Mahboub BH, Vats MG, Al Zaabi A, Iqbal MN, Safwat T,Al-Hurish F, Miravitlles M, Singh D, Asad K, Zeineldine S,Al-Hajjaj MS. Int J Chron Obstruct Pulmon Dis. 2017;12:2869–2890.Page 2885, Disclosure, the text “The authors report noconflicts of interest in this work” should read “BHM hasa pending patent for Samsum sublingual immunotherapywith the US Patent and Trademark Office. MM has receivedspeaker fees from Boehringer Ingelheim, Chiesi, Cipla,Menarini, Rovi, Bial, CSL Behring, Grifols and Novartis;consultancy fees from Boehringer Ingelheim, Chiesi,GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring,Laboratories Esteve, Mereo BioPharm, Verona Pharma,pH Pharma, Novartis and Grifols; and research grants fromGlaxoSmithKline and Grifols. DS has received speaking/consultancy fees from Apellis, AstraZeneca, BoehringerIngelheim, Chiesi, Cipla, Genentech, Glenmark, Merck,Mundipharma, Novartis, Peptinnovate, Pfizer, Pulmatrix,Skyepharma, Therevance and Verona; and research grantsfrom AstraZeneca, Boehringer Ingelheim, Chiesi, Glenmark,Merck, Mundipharma, Novartis, Pfizer, Pulmatrix, Teva,Therevance and Verona. The authors report no other conflictsof interest in this work”.Read the original article |